FDA Scrutiny on Sarepta - Search News

Order byBest matchMost fresh

News

FDA asks Sarepta to stop shipping gene therapy

· 2d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment died,

Continue reading

· 1d · on MSN

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths

Devdiscourse · 2d

FDA Scrutiny Intensifies as Sarepta Gene Therapy Faces Dire Setbacks

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Fierce Biotech2d

UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

2d

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results